Upon scrutiny of the individual secondary outcome measures, Ticlopidine monotherapy is the only therapy that can significantly reduce cardiovascular deaths, but it has been gradually withdrawn from clinical use because of a higher incidence of haematological disorders.[11] ADP inhibitors are the best treatment to prevent myocardial infarction with a 28% event rate reduction, and aspirin had the strongest protective effect against stroke with a 27% rate reduction. The gene discussed is WDTC1; the disease is stroke disorder.